cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2019.6.n458cardio-458Research ArticleОБЗОРREVIEWКоморбидность хронической обструктивной болезни лёгких и сердечно-сосудистых заболеваний: место терапии современными β-адреноблокаторамиComorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-AdrenoblockersБеленковЮ. Н.BelenkovYu. N.

Беленков Юрий Никитич  – академик РАН, профессор, д.м.н. заведующий кафедрой госпитальной терапии №1 лечебного факультета

Москва

Yuri Nikitich Belenkov  – Academician of Russian Science Academy, professor, MD, PhD, Chair of Hospital Department №1 of Medical Faculty

belenkovyn@gmail.comЦветковаО. А.TsvetkovaO. A.

Цветкова Ольга Александровна – профессор, д.м.н., кафедра госпитальной терапии №1 лечебного факультета

Москва

Olga Alexandrovna Tsvetkova  – professor, MD, PhD, Hospital Department №1 of Medical Faculty

oatsvetkova@mail.ruПриваловаЕ. В.PrivalovaE. V.

Привалова Елена  – профессор, д.м.н., кафедра госпитальной терапии №1 лечебного факультета

Москва

Elena Vitalievna Privalova  – professor, MD, PhD, Hospital Department №1 of Medical Faculty

ev_privalova@mail.ruАнГ. В.AnG. V.

Ан Галина Викторовна  – ассистент, к.м.н., кафедра госпитальной терапии №1 лечебного факультета

Москва

Galina Viktorovna An  – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty

an.galina@yahoo.comИльгисонисИ. С.IlgisonisI. S.

Ильгисонис Ирина Сергеевна  – доцент кафедры госпитальной терапии №1 лечебного факультета, к.м.н., врач-кардиолог

SPIN 6806-9299

Москва

ichekneva@yandex.ruВоронковаО. О.VoronkovaO. O.

Воронкова Ольга Олеговна  – ассистент, к.м.н., кафедра госпитальной терапии №1 лечебного факультета

Москва

Olga Olegovna Voronkova  – assistant professor, MD, PhD, Hospital Department №1 of Medical Faculty

voronkova.oo@gmail.comФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University)Russian Federation2019250620195964855Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/458

Хроническая обстpуктивная болезнь легких (ХОБЛ) занимает 4-ое место в структуре смертности населения в мире. Наличие сопутствующих заболеваний регистрируется у 96% пациентов ХОБЛ. Первое место среди них занимает сердечно-сосудистая патология (ишемическая болезнь сердца, артериальная гипертензия, хроническая сердечная недостаточность), которая в трети случаев является причиной смерти пациента. ХОБЛ и сердечно-сосудистые заболевания имеют общие факторы риска и общие механизмы патогенеза. Современные высокоселективные бета-адреноблокаторы (БАБ) снижают риск смертности и частоты обострений ХОБЛ, эффективны и безопасны в терапии пациентов с данной патологией.

Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality.  Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.

хроническая обструктивная болезнь легкихсопутствующие сердечно-сосудистые заболеванияβ-адреноблокаторыchronic obstructive pulmonary diseasecomorbid cardiovascular diseasescardioselective β-blockersПоддерживается «Проектом повышения конкурентоспособности ведущих российских университетов среди ведущих мировых научно образовательных центров 5–100»I.M. Sechenov’s First Moscow State Medical University of Ministry of Health (Sechenov University). No conflict of interest.ReferencesБарабанова Е. Н. GOLD (2017): что и почему изменилось в глобальной стратегии лечения хронической обструктивной болезни легких. Пульмонология. 2017;27(2):274-82. DOI: 10.18093/0869-0189-2017-27-2-274-282Barabanova E. N. GOLD 2017: What change were made in global strategy of treatment of chronic obstructive pulmonary disease and why? Russian Pulmonology. 2017;27(2):274–82. [Russian]. DOI: 10.18093/0869-0189-2017-27-2-274-282Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:183– 7. DOI: 10.2147/COPD.S153770Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:183– 7. DOI: 10.2147/COPD.S153770Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine. 2006;3(11):e442. DOI: 10.1371/journal.pmed.0030442Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine. 2006;3(11):e442. DOI: 10.1371/journal.pmed.0030442Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E et al. COPD in Never Smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63. DOI: 10.1378/chest.10-1253Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E et al. COPD in Never Smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63. DOI: 10.1378/chest.10-1253Chuchalin A, Khaltaev N, Antonov N, Galkin D, Manakov L, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014;12:963–74. DOI: 10.2147/COPD.S67283Chuchalin A, Khaltaev N, Antonov N, Galkin D, Manakov L, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014;12:963–74. DOI: 10.2147/COPD.S67283Григорьева Н. Ю., Майорова М. В., Кузнецов А. Н. Использование бета2-агонистов длительного действия в терапии хронической обструктивной болезни легких у больных с сопутствующей ишемической болезнью сердца. Современные технологии в медицине. 2017;9(1):156-61. DOI: 10.17691/stm2017.9.1.20Grigor’eva N. Y., Mayorova M. V., Kuznetsov A. N. Application of Long-Acting β2-Agonists in the Therapy of Chronic Obstructive Pulmonary Disease in Patients with Сonсomitant Ischemic Heart Disease. Modern Technologies in Medicine. 2017;9(1):156–61. [Russian]. DOI: 10.17691/stm2017.9.1.20Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2010;55(17):1780–7. DOI: 10.1016/j.jacc.2010.01.024Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology. 2010;55(17):1780–7. DOI: 10.1016/j.jacc.2010.01.024Bhatt SP, Dransfield MT. Chronicobstructivepulmonarydiseaseand cardiovascular disease. Translational Research. 2013;162(4):237– 51. DOI: 10.1016/j.trsl.2013.05.001Bhatt SP, Dransfield MT. Chronicobstructivepulmonarydiseaseand cardiovascular disease. Translational Research. 2013;162(4):237– 51. DOI: 10.1016/j.trsl.2013.05.001Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V et al. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(2):155–61. DOI: 10.1164/ rccm.201201-0034OCDivo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V et al. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(2):155–61. DOI: 10.1164/ rccm.201201-0034OCCurkendall SM, deLuise C, Jones JK, Lanes S, Stang MR, Goehring E et al. Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada. Annals of Epidemiology. 2006;16(1):63–70. DOI: 10.1016/j.annepidem.2005.04.008Curkendall SM, deLuise C, Jones JK, Lanes S, Stang MR, Goehring E et al. Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada. Annals of Epidemiology. 2006;16(1):63–70. DOI: 10.1016/j.annepidem.2005.04.008Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease. 2009;4:337–49. PMID: 19802349Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. International Journal of Chronic Obstructive Pulmonary Disease. 2009;4:337–49. PMID: 19802349McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisa- tion for exacerbation of COPD. European Respiratory Journal. 2012;39(5):1097–103. DOI: 10.1183/09031936.00124811McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisa- tion for exacerbation of COPD. European Respiratory Journal. 2012;39(5):1097–103. DOI: 10.1183/09031936.00124811Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine. 2008;102(9):1243–7. DOI: 10.1016/j. rmed.2008.04.010Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respiratory Medicine. 2008;102(9):1243–7. DOI: 10.1016/j. rmed.2008.04.010Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD. Chest. 2010;137(5):1091–7. DOI: 10.1378/chest.09-2029Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD. Chest. 2010;137(5):1091–7. DOI: 10.1378/chest.09-2029Кароли Н. А., Бородкин А. В., Ребров А. П. Диагностика хронической сердечной недостаточности у больных хронической обструктивной болезни легких. Клиническая медицина. 2015;93(5):50-6Karoli N. A., Borodkin A. V., Rebrov A. P. Diagnostics of chronic cardiac insufficiency in patients with chronic obstructive pulmonary disease. Clinical Medicine. 2015;93(5):50–6. [Russian]Майорова М. В., Григорьева Н. Ю., Кузнецов А. Н. Особенности ведения больных с хронической обструктивной болезнью легких, имеющих различные нарушения ритма. Медицинский альманах. 2018;1:101-5. DOI: 10.21145/2499-9954-2018-1-101-105Maiorova М. V., Grigor’eva N. Yu., Kuznetsov A. N. Features of management of patients with chronic obstructive pulmonary disease having various rhythm disturbances. Medical Almanac. 2018;1:101–5. [Russian]. DOI: 10.21145/2499-9954-2018-1-101-105Ли В. В., Тимофеева Н. Ю., Задионченко В. С., Адашева Т. В., Высоцкая Н. В. Современные аспекты ремоделирования сердца у больных хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии. 2018;14(3):379- 86. DOI: 10.20996/1819-6446-2018-14-3-379-386Lee V. V., Timofeeva N. Yu., Zadionchenko V. S., Adasheva T. V., Vysotskaya N. V. Recent aspects of cardiac remodeling in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2018;14(3):379–86. [Russian]. DOI: 10.20996/1819-6446-2018-14-3-379-386Леонова Е. И., Шехян Г. Г., Задионченко В. С., Адашева Т. В., Деев А. Д., Фёдорова И. В. Кардиопульмональные факторы, ассоциированные с фибрилляцией предсердий у больных хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии. 2016;12(1):26-30. DOI: 10.20996/1819-6446-2016-12-1-26-30Leonova E. I., Shechyan G. G., Zadionchenko V. S., Adasheva T. V., Deev A. D., Fedorova I. V. Cardiopulmonary factors associated with atrial fibrillation in patients with chronic obstructive pulmonary disease. Rational Pharmacotherapy in Cardiology. 2016;12(1):26–30. [Russian]. DOI: 10.20996/1819-6446-2016-12-1-26-30Григорьева Н. Ю., Капустина М. В., Кузнецов А. Н., Королева Т. В. Лечение ХОБЛ с сопутствующей сердечно-сосудистой патологией. Врач. 2016;7:70-3Grigor’eva N. Yu., Kapustina M. V., Kuznetsov A. N., Koroleva T. V. Treatment of chronic obstructive pulmonary disease with concomitant cardiovascular disease. The Doctor. 2016;7:70–3. [Russian]Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(10):982–8. DOI: 10.1164/rccm.201206-1113OCThomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012;186(10):982–8. DOI: 10.1164/rccm.201206-1113OCHogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2004;350(26):2645–53. DOI: 10.1056/NEJMoa032158Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L et al. The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2004;350(26):2645–53. DOI: 10.1056/NEJMoa032158Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Therapeutic Advances in Respiratory Disease. 2018;12:175346581775052. DOI: 10.1177/1753465817750524Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Therapeutic Advances in Respiratory Disease. 2018;12:175346581775052. DOI: 10.1177/1753465817750524Провоторов В. М., Будневский А. В., Шишкина Е. С. Динамика качества жизни у больных с хронической обструктивной болезни легких в стадии обострения и сопутствующей ишемической болезнью сердца при применении рофлумиласта. Перспективы науки. 2017;3(90):38-42Provotorov V. M., Budnevskiy A. V., Shishkina E. S. Dynamics of Quality of Life in Patients with Chronic Obstructive Pulmonary Disease in the Acute Stage and Related Ischemic Heart Disease When Using Roflumilast. Science Prospects. 2017;3(90):38–42. [Russian]Weir-McCall JR, Liu-Shiu-Cheong PS, Struthers AD, Lipworth BJ, Houston JG. Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:1755–65. DOI: 10.2147/COPD.S160077Weir-McCall JR, Liu-Shiu-Cheong PS, Struthers AD, Lipworth BJ, Houston JG. Disconnection of pulmonary and systemic arterial stiffness in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2018;13:1755–65. DOI: 10.2147/COPD.S160077Чучалин А. Г., Цеймах И. Я., Момот А. П., Мамаев А. Н., Карбышев И. А., Строзенко Л. А. Факторы тромбогенного риска у больных с обострением хронической обструктивной болезни легких. Клиническая медицина. 2015;93(12)18-23Chuchalin A. G., Tseimakh I. Ya., Momot A. P., Mamaev A. N., Karbyshev I. A., Strozenko L. A. Thrombogenic risk factors in patients with exacerbation of chronic obstructive pulmonary disease. Clinical Medicine. 2015;93(12):18–23. [Russian]Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG et al. A review of national guidelines for management of COPD in Europe. European Respiratory Journal. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG et al. A review of national guidelines for management of COPD in Europe. European Respiratory Journal. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015Jones DA, Timmis A, Wragg A. Novel drugs for treating angina. BMJ. 2013;347:f4726–f4726. DOI: 10.1136/bmj.f4726Jones DA, Timmis A, Wragg A. Novel drugs for treating angina. BMJ. 2013;347:f4726–f4726. DOI: 10.1136/bmj.f4726Wang W-H, Cheng C-C, Mar G-Y, Wei K-C, Huang W-C, Liu C-P. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart and Vessels. 2019; [Epub ahead of print]. DOI: 10.1007/s00380-019-01341-0Wang W-H, Cheng C-C, Mar G-Y, Wei K-C, Huang W-C, Liu C-P. Improving outcomes in chronic obstructive pulmonary disease by taking beta-blockers after acute myocardial infarction: a nationwide observational study. Heart and Vessels. 2019; [Epub ahead of print]. DOI: 10.1007/s00380-019-01341-0Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano Aet al. Beta-blocker, aspirin, andstatinusageafterfirst-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes. 2019; [Epub ahead of print]. DOI: 10.1093/ehjqcco/qcy063Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano Aet al. Beta-blocker, aspirin, andstatinusageafterfirst-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. European Heart Journal - Quality of Care and Clinical Outcomes. 2019; [Epub ahead of print]. DOI: 10.1093/ehjqcco/qcy063Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? European Respiratory Review. 2018;27(149):180057. DOI: 10.1183/16000617.0057-2018Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? European Respiratory Review. 2018;27(149):180057. DOI: 10.1183/16000617.0057-2018Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. 2001;344(22):1651–8. DOI: 10.1056/NEJM200105313442201Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. 2001;344(22):1651–8. DOI: 10.1056/NEJM200105313442201Taniguchi A, Miyahara N, Oda N, Morichika D, Ichihara E, Oze I et al. Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama. 2017;71(5):453–7. DOI: 10.18926/AMO/55446Taniguchi A, Miyahara N, Oda N, Morichika D, Ichihara E, Oze I et al. Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama. 2017;71(5):453–7. DOI: 10.18926/AMO/55446Zeng L, Hu, Liu J, Zhang H-Y, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clinical Interventions in Aging. 2013;8:1157. DOI: 10.2147/CIA.S49644Zeng L, Hu, Liu J, Zhang H-Y, Cui H. Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clinical Interventions in Aging. 2013;8:1157. DOI: 10.2147/CIA.S49644Ощепкова Е. В., Лазарева Н. В., Чазова И. Е. Особенности клиники и лечения больных артериальной гипертонией с ожирением (по данным Национального регистра артериальной гипертонии). Терапевтический архив. 2018;90(9):8-14. DOI: 10.26442/terarkh20189098-14Oshchepkova E. V., Lazareva N. V., Chazova I. E. Features of the clinics and treatment of patients with obesity and hyperten- sion (according to the National register of arterial hypertension). Therapeutic Archive. 2018;90(9):8–14. [Russian]. DOI: 10.26442/terarkh20189098-14D’Urzo A, Vogelmeier C. Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine. 2012;6(3):285–99. DOI: 10.1586/ers.12.20D’Urzo A, Vogelmeier C. Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine. 2012;6(3):285–99. DOI: 10.1586/ers.12.20Зафираки В. К., Скалецкий К. В., Намитоков А. М., Космачёва Е. Д., Шульженко Л. В., Омаров А. А. и др. Хроническая обструктивная болезнь легких как фактор неблагоприятного сердечно-сосудистого прогноза после чрескожных коронарных вмешательств при ишемической болезни сердца. Кардиология. 2015;55(10):41-5. PMID: 28294793Zafiraki V. K., Skaletskiy K. V., Namitokov A. M., Kosmacheva E. D., Shulzhenko L. V., Omarov A. A. et al. Chronic Obstructive Pulmonary Disease as a Factor of Unfavorable Cardiovascular Prognosis After Percutaneous Coronary Interventions in Ischemic Heart Disease. Kardiologiia. 2015;55(10):41–5. [Russian] PMID: 28294793]Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews. 2017;22(6):753–63. DOI: 10.1007/s10741-017-9646-zPetta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N et al. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews. 2017;22(6):753–63. DOI: 10.1007/s10741-017-9646-zСтаценко М. Е., Деревянченко М. В. Место β-адреноблокаторов в лечении сердечно-сосудистых заболеваний у больных хронической обструктивной болезнью легких. Кардиология. 2012;52(12):57-63Statsenko M. E., Derevyanchenko M. V. Th Place of β-adrenoblockers in the Treatment of Cardiovascular Disease in Patients With Chronic Obstructive Pulmonary Disease. Kardiologiia. 2012;52(12):57–63. [Russian]Martiniuc C, Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi. 2012;116(1):218–21. PMID: 23077899Martiniuc C, Branishte T. The use of beta blocker Nebivolol in patients with chronic obstructive pulmonary disease in association with arterial hypertension. Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi. 2012;116(1):218–21. PMID: 23077899Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):535–40. PMID: 18268926Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2(4):535–40. PMID: 18268926Ni Y, Shi G, Wan H. Use of Cardioselective β-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. Journal of International Medical Research. 2012;40(6):2051–65. DOI: 10.1177/030006051204000602Ni Y, Shi G, Wan H. Use of Cardioselective β-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials. Journal of International Medical Research. 2012;40(6):2051–65. DOI: 10.1177/030006051204000602Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under- use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM: An International Journal of Medicine. 2005;98(7):493–7. DOI: 10.1093/qjmed/hci080Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under- use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM: An International Journal of Medicine. 2005;98(7):493–7. DOI: 10.1093/qjmed/hci080Гурова А. Ю., Чаплыгин А. В., Свет А. В., Морозова Т. Е., Цветкова О. А. Особенности рациональной фармакотерапии бета-адреноблокаторами при сочетании ишемической болезни сердца и хронической обструктивной болезни легких. Лечащий врач. 2012;2:15Gurova A. Yu., Chaplygin A. V., Svet A. V., Morozova T. E., Tsvetkova O. A. Features of rational pharmacotherapy with beta-blockers in combination of coronary heart disease and chronic obstructive pulmonary disease. Attending physician. 2012;2:15. [Russian]Peters JI, Gomez-Dinger PL, Freeman GL, Galbreath AD, Smith PB. Use of Beta Blockers in Congestive Heart Failure(CHF) Patients with COPD and/or Asthma. Chest. 2004;126(4):921S. DOI: 10.1378/chest.126.4_MeetingAbstracts.921SPeters JI, Gomez-Dinger PL, Freeman GL, Galbreath AD, Smith PB. Use of Beta Blockers in Congestive Heart Failure(CHF) Patients with COPD and/or Asthma. Chest. 2004;126(4):921S. DOI: 10.1378/chest.126.4_MeetingAbstracts.921SЦветкова О. А., Веселовская М. В. Эффективность применения кардиоселективного бета1-адреноблокатора бисопролола у больных хронической обструктивной болезнью легких в сочетании с ишемической болезнью сердца. Терапевтический архив. 2007;79(3):25-9Tsvetkova O. A., Veselovskaya M. V. Efficacy of a cardioselec-tive betal-adrenoblocker bisoprolol in patients with chronic obstructive pulmonary disease in combination with ischemic heart disease. Therapeutic Archive. 2007;79(3):25–9. [Russian]Гельтцер Б. И., Курпатов И. Г., Котельников В. Н., Заяц Ю. В. Хроническая обструктивная болезнь легких и цереброваскулярные заболевания: структурно-функциональные и клинические аспекты коморбидности. Терапевтический архив. 2018;90(3):81-8. DOI: 10.26442/terarkh201890381-88Geltser B. I., Kurpatov I. G., Kotelnikov V. N., Zayats Yu. V. Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity. Therapeutic Archive. 2018;90(3):81–8. [Russian]. DOI: 10.26442/terarkh201890381-88Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE. 2014;9(11):e113048. DOI: 10.1371/journal.pone.0113048Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS ONE. 2014;9(11):e113048. DOI: 10.1371/journal.pone.0113048Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP et al. Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. Journal of Cardiac Failure. 2007;13(10):797–804. DOI: 10.1016/j.cardfail.2007.07.012Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP et al. Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. Journal of Cardiac Failure. 2007;13(10):797–804. DOI: 10.1016/j.cardfail.2007.07.012Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK et al. Effects of acute and chronic administration of -adrenoceptor ligands on airway function in a murine model of asthma. Proceedings of the National Academy of Sciences. 2004;101(14):4948–53. DOI: 10.1073/pnas.0400452101Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK et al. Effects of acute and chronic administration of -adrenoceptor ligands on airway function in a murine model of asthma. Proceedings of the National Academy of Sciences. 2004;101(14):4948–53. DOI: 10.1073/pnas.0400452101Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar- Aouchiche Z et al. Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model. American Journal of Respiratory Cell and Molecular Biology. 2008;38(3):256–62. DOI: 10.1165/rcmb.2007-0279RCNguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar- Aouchiche Z et al. Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model. American Journal of Respiratory Cell and Molecular Biology. 2008;38(3):256–62. DOI: 10.1165/rcmb.2007-0279RC

The authors declare that there are no conflicts of interest present.